prikaz prve stranice dokumenta Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society
  Preuzmi
PDF 272.79 KB
Znanstveni rad - Pregledni rad
Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society
Croatian Medical Journal, 63 (2022), 4; 379-388. https://doi.org/10.3325/cmj.2022.63.379
Habek, Mario; Adamec, Ivan; Barun, Barbara; Bašić Kes, Vanja; Bogoje Raspopović, Andrijana; Duka Glavor, Klaudia; Gabelić, Tereza; Grzinčić, Tihana; Jukić, Mirjam; Jurašić, Miljenka-Jelena; Kiđemet-Piskač, Spomenka; Komšo, Milica; Rimac, Julija; Lazibat, Ines; Lukić, Branka; Marčinko, Anita; Matijaca, Meri; Ratković, Marija; Šapina, Lidija; Vuletić, Vladimira; Mirošević Zubonja, Tea; Krbot Skorić, Magdalena Više autora...

Citiranost:
,
Citirajte ovaj rad

Habek, M., Adamec, I., Barun, B., Bašić Kes, V., Bogoje Raspopović, A., Duka Glavor, K. ... Krbot Skorić, M. (2022). Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society. Croatian Medical Journal, 63. (4), 379-388. doi: 10.3325/cmj.2022.63.379

Habek, Mario, et al. "Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society." Croatian Medical Journal, vol. 63, br. 4, 2022, str. 379-388. https://doi.org/10.3325/cmj.2022.63.379

Habek, Mario, Ivan Adamec, Barbara Barun, Vanja Bašić Kes, Andrijana Bogoje Raspopović, Klaudia Duka Glavor, Tereza Gabelić, et al. "Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society." Croatian Medical Journal 63, br. 4 (2022): 379-388. https://doi.org/10.3325/cmj.2022.63.379

Habek, M., et al. (2022) 'Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society', Croatian Medical Journal, 63(4), str. 379-388. doi: 10.3325/cmj.2022.63.379

Habek M, Adamec I, Barun B, Bašić Kes V, Bogoje Raspopović A, Duka Glavor K, i sur.. Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society. Croatian Medical Journal [Internet]. 2022. [pristupljeno 25.03.2025.];63(4):379-388. doi: 10.3325/cmj.2022.63.379

M. Habek, et al., "Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society", Croatian Medical Journal, vol. 63, br. 4, str. 379-388, 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:089481. [Citirano: 25.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:089481
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society
AutorMario Habek
AutorIvan Adamec
AutorBarbara Barun
AutorVanja Bašić Kes
AutorAndrijana Bogoje Raspopović
AutorKlaudia Duka Glavor
AutorTereza Gabelić
AutorTihana Grzinčić
AutorMirjam Jukić
AutorMiljenka-Jelena Jurašić
AutorSpomenka Kiđemet-Piskač
AutorMilica Komšo
AutorJulija Rimac
AutorInes Lazibat
AutorBranka Lukić
AutorAnita Marčinko
AutorMeri Matijaca
AutorMarija Ratković
AutorLidija Šapina
AutorVladimira Vuletić
AutorTea Mirošević Zubonja
AutorMagdalena Krbot Skorić
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Untreated multiple sclerosis (MS) irretrievably leads to severe neurological impairment. In European health care systems, patient access to disease modifying therapies (DMT) is often confined to more advanced stages of the disease because of restrictions in reimbursement. A discrepancy in access to DMTs is evident between West and East European countries. In order to improve access to DMTs for people with MS (pwMS) living in Croatia, the Croatian Neurological Society issued new recommendations... Više for the treatment of relapsing MS. The aim of this article is to present these recommendations. The recommendations for platform therapies are to start DMT as soon as the diagnosis is made. If poor prognostic criteria are present (≥9 T2 or FLAIR lesions on the initial brain and spinal cord magnetic resonance imaging [MRI] or ≥3 T1 lesions with postcontrast enhancement on the initial brain and spinal cord MRI or Expanded Disability Status Scale after treatment of the initial relapse ≥3), high-efficacy DMT should be initiated. If pwMS experience ≥1 relapse or ≥3 new T2 lesions while on platform therapies, they should be switched to high-efficacy DMT. Further efforts should be made to enable early and unrestricted access to high-efficacy DMT with a freedom of choice of an appropriate therapy for expert physicians and pwMS. The improvement of access to DMT achieved by the implementation of national treatment guidelines in Croatia can serve as an example to national neurological societies from other Eastern European countries to persuade payers to enable early and unrestricted treatment of pwMS. Sakrij dio sažetka
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian Medical Journal
Brojčani podacivol. 63, br. 4, str. 379-388
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2022.63.379
URN:NBNurn:nbn:hr:220:089481
Datum objave publikacije2022
URL dokumentahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468732/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-06-17 10:44:53
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.